| MOCHIDA PHARMACEUTICAL CO., LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110118350 | COMPOSITION FOR PREVENTING CARDIOVASCULAR EVENT IN HIGH-RISK PATIENT - Provided is a pharmaceutical composition for reducing the risk in a patient at high risk for occurrence and/or recurrence of a cardiovascular event by administering the composition to the patient with a high ratio of oleic acid to stearic acid in plasma. The pharmaceutical composition contains ethyl icosapentate as its effective component. The composition is expected to reduce the risk in the patient at high risk for occurrence and/or recurrence of a cardiovascular event, and particularly to have a preventive effect on occurrence and/or recurrence of a cardiovascular event in the patient with a high ratio of oleic acid to stearic acid in plasma. | 05-19-2011 |
| 20110112071 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE - A compound represented by formula (I′): | 05-12-2011 |
| 20110086381 | METHOD FOR EVALUATION OF FUNCTION OF PHAGOCYTE - A novel convenient method for evaluating the function of a phagocyte is provided. The method assays sCD14-ST, which is a humoral factor specifically produced in phagocytosis by the phagocyte and which is stable enough for use in an assay. Also provided is a method for detecting diseases associated with the phagocytosis by the phagocyte. | 04-14-2011 |
| 20100254951 | Nerve Regeneration Promoting Agent - A neuronal differentiation promoting agent for neural stem cells comprising, as an active ingredient, at least one member selected from the group consisting of ω-3 unsaturated fatty acids and ω-6 unsaturated fatty acids having 18 to 22 carbon atoms, and derivatives thereof. The agent can be used for induction of differentiation of neural stem cells and is useful for treating and/or preventing a variety of neurological diseases, and in the fields of nerve transplantation and/or regenerative medicine for nerves. | 10-07-2010 |
| 20100048506 | Composition for treating arthritic disorder - The present invention provides compositions and methods for treating a joint disease containing as an active ingredient thereof a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for treating a joint disease which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing cartilage injuries, suppressing inflammation and pain of joint tissue, inhibiting degeneration of synovial tissue, and inhibiting osteochondral destruction. | 02-25-2010 |
| 20100016285 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE - The blow-described formula (I)
| 01-21-2010 |
| 20080292619 | Pharmaceutical Composition Containing Meltrin Antagonist - Mainly concerning the pharmaceutical field, it is intended to exert an inhibitory effect on the function of meltrin α of promoting the differentiation of adipocytes by preparing a compound serving as an antagonist to meltrin α (for example, an antisense inhibiting the expression of a meltrin α gene or an anti-meltrin α antibody capable of inhibiting the physiological activity of meltrin α) and administering the same. By employing such a meltrin α antagonist as described above as the active ingredient, it becomes possible to provide a preventive/remedy which is efficacious against fatness, obesity or various diseases caused by obesity or relating thereto such as diabetes. | 11-27-2008 |
